SHUKRAPHAR vs OMAXE: Stock Comparison
Head-to-head financial and trading comparison between Shukra Pharmaceuticals Limited (SHUKRAPHAR) and Omaxe Limited (OMAXE) in the Cross-Sector Peers sector.
SHUKRAPHAR
NSE: SHUKRAPHAROMAXE
NSE: OMAXEKey Metrics Comparison Table
| Metric | SHUKRAPHAR | OMAXE | Edge / Winner |
|---|---|---|---|
| Current Market Price (CMP) | ₹66.94 | ₹100.19 | — |
| 1-Year Price Return | +61.61% | +27.02% | SHUKRAPHAR (34.59% higher) |
| 52-Week High | ₹72.58 | ₹136.38 | — |
| 52-Week Low | ₹41.42 | ₹73.17 | — |
| 30-Day Annualized Volatility | 64.68% | 76.35% | SHUKRAPHAR (Steadier) |
| 30-Day Average Daily Volume | 6,592,919 | 4,478,010 | SHUKRAPHAR (Higher Liquidity) |
| Statutory Cost to Trade ₹1 Lakh | ₹118.50 | ₹118.50 | Identical statutory tariff |
Frequently Asked Questions
Between SHUKRAPHAR and OMAXE, which stock gave better returns over the last year?
SHUKRAPHAR has outperformed OMAXE over the past 12 months with a gain of 61.61% compared to 27.02%.
Which stock is less volatile: SHUKRAPHAR or OMAXE?
SHUKRAPHAR demonstrated lower price volatility (64.68% annualized) compared to OMAXE (76.35%). Lower volatility generally indicates steadier price action during market downturns.
What is the statutory cost to buy ₹1,00,000 of SHUKRAPHAR vs OMAXE?
Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).
Are SHUKRAPHAR and OMAXE direct sector competitors?
Yes, both companies operate within the Cross-Sector Peers sector in India and are actively tracked as sector peers by institutional and retail market participants.